143 related articles for article (PubMed ID: 10908891)
1. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.
Kemppainen N; Ruottinen H; Nâgren K; Rinne JO
Neurology; 2000 Jul; 55(2):205-9. PubMed ID: 10908891
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis.
Rinne JO; Ruottinen HM; Någren K; Aberg LE; Santavuori P
Neuropediatrics; 2002 Jun; 33(3):138-41. PubMed ID: 12200743
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
5. Striatal dopamine D1 and D2 receptors in burning mouth syndrome.
Hagelberg N; Forssell H; Rinne JO; Scheinin H; Taiminen T; Aalto S; Luutonen S; Någren K; Jääskeläinen S
Pain; 2003 Jan; 101(1-2):149-54. PubMed ID: 12507709
[TBL] [Abstract][Full Text] [Related]
6. Striatal dopamine D1 receptors in narcolepsy: a PET study with [11C]NNC 756.
Rinne JO; Hublin C; Partinen M; Ruottinen H; Någren K; Lehikoinen P; Ruotsalainen U; Laihinen A
J Sleep Res; 1996 Dec; 5(4):262-4. PubMed ID: 9065878
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
8. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
9. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
10. Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET.
Rosa-Neto P; Doudet DJ; Cumming P
Neuroimage; 2004 Jul; 22(3):1076-83. PubMed ID: 15219579
[TBL] [Abstract][Full Text] [Related]
11. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
12. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography.
Rinne JO; Sahlberg N; Ruottinen H; Någren K; Lehikoinen P
Neurology; 1998 Jan; 50(1):152-6. PubMed ID: 9443472
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride.
Khan N; Antonini A; Parkes D; Dahlitz MJ; Meier-Ewert K; Weindl A; Leenders KL
Neurology; 1994 Nov; 44(11):2102-4. PubMed ID: 7969966
[TBL] [Abstract][Full Text] [Related]
14. Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man.
Hagelberg N; Kajander JK; Någren K; Hinkka S; Hietala J; Scheinin H
Synapse; 2002 Jul; 45(1):25-30. PubMed ID: 12112410
[TBL] [Abstract][Full Text] [Related]
15. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor.
Karlsson P; Farde L; Halldin C; Swahn CG; Sedvall G; Foged C; Hansen KT; Skrumsager B
Psychopharmacology (Berl); 1993; 113(2):149-56. PubMed ID: 7855175
[TBL] [Abstract][Full Text] [Related]
16. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
17. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors.
Halldin C; Foged C; Chou YH; Karlsson P; Swahn CG; Sandell J; Sedvall G; Farde L
J Nucl Med; 1998 Dec; 39(12):2061-8. PubMed ID: 9867142
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
19. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors.
Rinne JO; Iivanainen M; Metsähonkala L; Vainionpää L; Pääkkönen L; Någren K; Helenius H
J Neural Transm (Vienna); 2004 Jan; 111(1):59-67. PubMed ID: 14714216
[TBL] [Abstract][Full Text] [Related]
20. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
